Mounjaro®
Starting from £179.99/mo
Start journey Learn morePen mechanics, needle systems and what the differences mean for you day to day
The myth worth correcting first: they're both 'injection pens', so they must work the same way
This is the assumption most people bring to the comparison, and it is understandable. Both medicines are given once a week under the skin, both come in pre-filled devices, and both look vaguely similar in pharmacy photographs. Stop there, though, and you have missed the most practically important detail.
Mounjaro (tirzepatide, made by Eli Lilly) is dispensed as a KwikPen. One pen contains four doses. You use it every week for a month, capping and storing it in the fridge between injections. The pen is calibrated to deliver a pre-set volume automatically, there is no needle to attach before you inject.
Wegovy (semaglutide, made by Novo Nordisk) works on a completely different system. Each pen is single-use: one injection, one pen, then it is done. A fresh pen is used every week. The needle is integrated into the auto-injector mechanism and locks after use. If you are familiar with how Wegovy and Mounjaro compare clinically, this device difference is separate to the pharmacology, two medicines, two different delivery platforms, not interchangeable in any practical sense.
The needles themselves differ in gauge, length and attachment design. Using a Wegovy needle on a Mounjaro pen, or vice versa, is not clinically appropriate; the manufacturers' specifications exist for a reason and the patient information leaflet for each product is the definitive reference.
What the device difference means when you are switching between the two
People switch medicines for various reasons, stock availability, a prescriber's clinical recommendation, cost, or side-effect profile. The device transition is one of the practical questions that comes up immediately, and it is a fair one.
Because the injection systems are distinct, there is no carry-over technique. If you are used to the four-dose Mounjaro KwikPen and move to Wegovy, you are starting fresh with a single-dose auto-injector. The injection sites are the same (abdomen, outer thigh, upper arm), and the rotation principle applies to both, but the handling steps differ. Our prescribers walk through this with patients, and you can read more about what happens when you switch from Mounjaro to Wegovy, including the practical and clinical considerations involved.
Sharps disposal applies to both. Each used pen or detached needle is clinical waste. A purpose-made container keeps things safe, a 1-litre sharps container is the right size for home use and is a good habit to establish from your first injection, whichever pen you are using.
Storage differs too, though both require refrigeration. The exact room-temperature windows vary and are different between the two products, always check the patient information leaflet for your specific pen rather than relying on general advice, because the SmPC wording is the authority here.
A direct comparison of the two injection systems
The table below captures the key device-level differences factually. Clinical results and eligibility are a separate matter, see the Mounjaro vs Wegovy cost guide and the treatment overview for the broader picture.
| Feature | Mounjaro (tirzepatide) | Wegovy injection (semaglutide 2.4mg / 7.2mg) |
|---|---|---|
| Pen type | Multi-dose KwikPen (4 weekly doses per pen) | Single-dose auto-injector (1 pen per week) |
| Needle attachment | Integrated; no separate attachment step in normal use | Integrated auto-injector; locks after single use |
| Doses per device | 4 | 1 |
| Available UK strengths | 2.5, 5, 7.5, 10, 12.5, 15 mg [Source: eMC SmPC] | 0.25 mg up to 2.4 mg maintenance; 7.2 mg pen also MHRA-approved [Source: MHRA, April 2026] |
| Needles interchangeable? | No, systems are incompatible; follow the PIL for each product | |
| Storage | Refrigerated; limited room-temperature window per PIL | Refrigerated; limited room-temperature window per PIL |
The MHRA approved a dedicated single-dose 7.2mg Wegovy pen on 14 April 2026, as confirmed on GOV.UK. This adds another distinct device format to the semaglutide family, again, not compatible with Mounjaro hardware.
Which pen is the right fit, and how the clinical decision gets made
Device preference is a real factor. Some people prefer the Mounjaro KwikPen's once-a-month delivery rhythm and the fact that four doses come in one unit. Others prefer a fully disposable weekly pen with nothing to store between uses. Neither preference is wrong, but it is one of many things a prescriber weighs alongside your medical history, current medications and weight-management goals.
If you are curious about using both medicines at once, the short answer is that this is not clinically appropriate; the Mounjaro and Wegovy together page explains why. Likewise, the full clinical picture of how these medicines differ (mechanism, trial evidence, NHS eligibility) is covered in detail on the Wegovy vs Mounjaro comparison.
At nume, a real clinician reviews every consultation. There is no algorithm deciding what you are prescribed; a GPhC-registered prescriber looks at your full picture and makes the call. You can explore your options and start a free consultation to have the device question (and the clinical one) answered properly. Which medicine suits you is a decision our prescribers make with you, not for you.
Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.